Gardant Pharmaceuticals, Inc. GRDP To be aquired
Gardant Pharmaceuticals today announced it has signed an agreement
to be acquired by Switch Pharma Ltd. Shares of Switch Pharma Ltd., which is
currently in the process of going public in London, will be issued to acquire
Gardant Pharmaceuticals. Pursuant to the agreement, the Switch Pharma Ltd.
shares issued in the transaction must be trading for at least $1.38 per share
when the shares of Switch Pharma Ltd. commence trading publicly in London.
Shareholders of Gardant will receive one share of Switch Pharma for every
Gardant share owned. The transaction is expected to close on September 30th
subject to requisite approvals.
Switch Pharma is a company that is focused on the development and
commercialization of proprietary, innovative and differentiated therapeutic drug
products. The Company's core strategy is to focus on the uses of different
applications for known drugs. The Company's management believes that this method
allows Switch Pharma to be selective about the drugs it develops and gives the
Company the advantage of already knowing the safety and toxicology profiles of
known drugs before identifying new indications, thereby saving considerable
expense and time. The existing therapeutic drugs have typically been marketed
for a number of years, have established safety profiles and can be developed for
new clinical indications. Utilizing this development focus, the Company seeks to
reduce the risk, time and cost of new product development as compared to the
development of new chemical entities. Gardant Pharmaceuticals was attractive to
Switch Pharma because of its risk balanced portfolio and the fact that the
majority of the portfolio now consists of oncology-focused compounds, as
oncology applications and therapeutics are the intended focus of Switch Pharma
going forward. Of the eight re-purposed therapeutic products that Switch
currently is seeking to develop, two are for the oncology marketplace.
Gardant Pharmaceuticals previously announced the spin-off to its shareholders of
record on July 31, 2006 of its shares of Genaderm, Inc., Avantogen Oncology,
Inc. (f/k/a Innovate Oncology, Inc.), and Amilar Pharmaceuticals Inc. Those
spin-offs will proceed as planned, subject to receipt of requisite approvals.
Gardant previously announced the spin-off of its shares of Accura Pharma PLC to
shareholders of record as of April 21, 2006. Gardant has been advised that
Accura Pharma PLC anticipates that its common shares will commence trading in
London during the week of September 12, 2006.
About Gardant Pharmaceuticals, Inc.
Gardant Pharmaceuticals, Inc., after spinning-off certain subsidiaries, is
focused on developing a portfolio of compounds which have an emphasis on
treating cancer. The Company is focused on developing and commercializing novel
pharmaceutical compounds in an efficient, cost-effective way. Gardant seeks to
use its academic, industry and capital market relationships to expedite drug
development and raise capital to create and fund compounds. Gardant's strategy
relies on its development network for research, clinical development and project
management to guide early-stage compounds from the discovery process through to
Phase II/III development where incremental value can be created.
Gardant Pharmaceuticals, Inc. Safe Harbor Statement
Certain statements contained herein are "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995).
Because these statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements. Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking statements
include, but are not limited to: the ability of Gardant to finance its
activities on commercially acceptable terms, in timely fashion, or at all; risks
associated with pre-clinical and clinical developments in the biopharmaceutical
industry in general and in Gardant's compounds under development in particular;
the potential failure of Gardant's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the early stage of
Gardant's compounds under development; failure to successfully implement or
complete clinical trials; failure to receive marketing clearance from regulatory
agencies for our compounds under development; acquisitions, divestitures,
mergers, licenses or strategic initiatives that change Gardant's business,
structure or projections; the development of competing products; uncertainties
related to Gardant's dependence on third parties and partners; and those risks
described in the filings with the SEC, all of which are under Gardant's prior
name as Mobile Design Concepts, Inc. Gardant disclaims any obligation to update
these forward-looking statements.
